Avadel Pharmaceuticals — Investor Presentation (September 2019)
14 slides from Avadel Pharmaceuticals's investor presentation, Sep 24, 2019
Slide 1: Avadel Pharmaceuticals plc Company Overview - September 2019
The Power of Medicine. Reinvented. © Avadel 2019. All rights reserved. Avadel Pharmaceuticals plc Nasdaq: AVDL Company Overview - September 2019
Slide 2: Safe Harbor
2 © Avadel 2019. All rights reserved. Safe Harbor This presentation may include forward - looking statements within the meaning of Section 27 A of the Securities Act of 1933 and Section 21 E of the Securities Exchange Act of 1934 . The words “will,” “may,” “believe,” “expect,” “anticipate,” “estimat
Slide 3: The New Avadel
© Avadel 2019. All rights reserved. THE NEW AVADEL We are an emerging bio - pharmaceutical company. Our primary focus is on the development and potential FDA approval for our Phase III orphan designated once - nightly sodium oxybate , FT218, for the treatment of excessive daytime sleepiness (EDS) an
Slide 4: The New Avadel 2019 YTD – Transformational Change
4 © Avadel 2019. All rights reserved. The New AVADEL 2019 YTD – Transformational Change… Building Momentum Refocused Restructured Recruited • Strategically refocused on FT218, a significant late stage opportunity • Orphan designated Phase III investigational asset • REST - ON clinical trial 94% enro
Slide 5: FT218 Phase 3 study REST-ON is 94% enrolled
5 © Avadel 2019. All rights reserved. • The FT218 Phase 3 study, REST - ON, is 94% enrolled • Enrollment to be completed by end of 2019 (target); data readout in Q2 2020 • No new chemical entity (NCE) risk as a formulation of a well understood molecule being filed under a 505(b)(2) pathway • Single
Slide 6: Narcolepsy Overview
6 CNS/SLEEP © Avadel 2019. All rights reserved. References: 1. Narcolepsy Network foundation http://narcolepsynetwork.org/about - narcolepsy/ 2. Xyrem 2Q19 Financial Results slide presentation, published August 6, 2019 Narcolepsy Overview A sleep disorder, involving irregular patterns in Rapid Eye M
Slide 7: Transforming the way we treat patients
7 CNS/SLEEP © Avadel 2019. All rights reserved. Transforming the way we treat patients Sodium Oxybate 2x - nightly is the only FDA - approved treatment for cataplexy and EDS in narcolepsy Current treatment paradigm The Micropump™ delivery technology is designed to deliver one single dose at bedtime
Slide 8: A Better Solution
8 CNS/SLEEP © Avadel 2019. All rights reserved. A Better Solution Despite being the standard of care, only 9% of patients are prescribed 2x - nightly sodium oxybate as 1 st line therapy 1 Improved compliance Approximately 44% of newly treated patients discontinue twice - nightly sodium oxybate withi
Slide 9: An Overview of the Phase 3 Trial, REST-ON
9 CNS/SLEEP © Avadel 2019. All rights reserved. An Overview of the Phase 3 Trial, REST - ON • Randomized, double - blind, parallel - group placebo - controlled study with 1:1 randomization to FT218 or placebo in patients with Narcolepsy, either NT1 or NT2 • Primary objective is to evaluate the effic
Slide 10: REST-ON Statistical Analysis Plan and Protocol Amendment
10 CNS/SLEEP © Avadel 2019. All rights reserved. REST - ON Statistical Analysis Plan (SAP) and Protocol Amendment • Modified the statistical analysis of the primary endpoint from two doses in parallel (7.5 or 9 g) to each dose sequentially (9 g followed by 7.5 g) • If 9g analysis is positive, repeat
Slide 11: Hospital Franchise
11 HOSPITAL © Avadel 2019. All rights reserved. 3 commercial sterile injectable products used in the hospital setting 4 th sterile injectable NDA accepted in May 2019; PDUFA date of December 15, 2019; estimated market of $30M+ AKOVAZ ™ BLOXIVERZ ™ VAZCULEP ™ The Hospital Franchise H1 2019 revenues o
Slide 12: Performance and Financial Highlights
12 © Avadel 2019. All rights reserved. Performance and Financial Highlights • Refocused on FT218 , a Phase 3 opportunity • Operationally restructured company resulting in >$80M in annualized cost reductions • Strengthened management, clinical and medical teams • Secured FT218 protocol amendment YTD
Slide 13: FT218 Phase 3 study REST-ON is 94% enrolled
13 © Avadel 2019. All rights reserved. • The FT218 Phase 3 study, REST - ON, is 94% enrolled • Enrollment to be completed by end of 2019 (target); data readout in Q2 2020 • No new chemical entity (NCE) risk as a formulation of a well understood molecule being filed under a 505(b)(2) pathway • Single
Slide 14: Thank you
The Power of Medicine. Reinvented. © Avadel 2019. All rights reserved. Thank you September 2019
Avadel Pharmaceuticals — Investor Presentation (September 2019) on 6ix